Syndax Announces Participation at the 2026 Guggenheim Emerging Outlook: Biotech Summit
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals (NASDAQ:SNDX) had its price target raised by analysts at Mizuho from $410.00 to $600.00. They now have an "outperform" rating on the stock.
Syndax Pharmaceuticals, Inc. (SNDX): A Bull Case Theory [Yahoo! Finance]
Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]